Classification of epileptic drugs Safer drug in pregnancy _ Lorazepam Highly teratogenic _ valproate Alzeihmers Classification Proton pump inhibitiors Hit and Run drugs
Reading File
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Reading File
Reading File
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Reading File
Finding Sources
Reading File
Finding Sources
Reading File
I now have excellent textbook data across all topics. Let me compile the comprehensive answer.
1. Classification of Antiepileptic Drugs (AEDs)
By Generation
First-Generation (Older/Classical)
| Drug | Mechanism | Seizure Type |
|---|---|---|
| Phenytoin | Sodium channel inhibitor | Focal, generalized |
| Carbamazepine | Sodium channel inhibitor | Focal, generalized |
| Phenobarbital | GABA potentiation | Focal, generalized |
| Valproic acid | Multiple: GABA potentiation, NMDA inhibition, Na+ & T-type Ca2+ channel inhibition | Focal, generalized, absence |
| Ethosuximide | T-type calcium channel inhibition | Absence seizures |
| Clonazepam/Diazepam | GABA potentiation | Various |
Second-Generation (Newer)
| Drug | Mechanism | Seizure Type |
|---|---|---|
| Lamotrigine | Sodium channel inhibitor | Focal, generalized |
| Topiramate | Multiple: GABA potentiation, AMPA inhibition, Na+ & Ca2+ channel inhibition | Focal, generalized |
| Levetiracetam | SV2A modulation | Focal, generalized |
| Oxcarbazepine | Sodium channel inhibitor | Focal |
| Zonisamide | Sodium channel inhibition | Focal, generalized |
| Lacosamide | Sodium channel inhibition | Focal, generalized |
Third-Generation (Newest)
| Drug | Mechanism | Seizure Type |
|---|---|---|
| Brivaracetam | SV2A modulation | Focal, generalized |
| Eslicarbazepine | Sodium channel inhibitor | Focal (adjunct) |
| Perampanel | AMPA receptor antagonist | Focal, generalized |
By Mechanism of Action
- Sodium channel blockers: Phenytoin, Carbamazepine, Oxcarbazepine, Eslicarbazepine, Lamotrigine, Lacosamide, Zonisamide
- GABA potentiators: Phenobarbital, Benzodiazepines, Topiramate, Vigabatrin, Tiagabine
- Calcium channel (T-type) blockers: Ethosuximide, Valproate
- SV2A modulators: Levetiracetam, Brivaracetam
- Multiple mechanisms: Valproate, Topiramate
(Adams and Victor's Principles of Neurology, 12th Edition, Table 15-5)
2. AEDs in Pregnancy
Safer Drug - Lorazepam
Lorazepam is used as the first-line drug for status epilepticus in pregnancy and is relatively safer in acute settings. For chronic epilepsy management, levetiracetam is currently preferred as it carries no increased risk of major congenital malformations compared to unexposed pregnancies.
Key points regarding pregnancy safety:
- Phenytoin, carbamazepine, phenobarbital, topiramate, and valproate all carry higher odds of major congenital malformations
- Lamotrigine and levetiracetam have the best safety profiles among maintenance AEDs in pregnancy
- Women on enzyme-inducing AEDs (phenytoin, carbamazepine, topiramate) require higher doses of estrogen in oral contraceptives
- Folate supplementation before conception is recommended for all women on AEDs
(Creasy & Resnik's Maternal-Fetal Medicine; Adams and Victor's Principles of Neurology)
Highly Teratogenic - Valproate
Valproate carries the highest teratogenic risk of all AEDs:
- Risk of neural tube defects (spina bifida) - up to 1-2%
- Risk of major malformations up to 10.3% (vs. 2-3% background)
- Associated with lower IQ and neurodevelopmental delay in exposed children
- Most neurologists avoid valproate entirely in women of childbearing age who wish to become pregnant
- If it must be used, folic acid supplementation is essential (though benefit for valproate-specific defects is less clear)
(Kaplan & Sadock's Comprehensive Textbook of Psychiatry; Adams and Victor's Principles of Neurology)
3. Alzheimer's Disease Classification
NIA-AA 2018 Research Framework (A/T/N Biomarker Classification)
According to the 2018 National Institutes of Aging - Alzheimer's Association (NIA-AA) research framework, AD is no longer defined by clinical consequences alone, but by its underlying pathology measured by biomarkers:
- A - Amyloid (amyloid plaques on PET or CSF Abeta42)
- T - Tau (neurofibrillary tangles on tau-PET or CSF phospho-tau)
- N - Neurodegeneration/Neuronal injury (FDG-PET, MRI atrophy, CSF total tau)
Clinical Stages (DSM-5 / McKhann Criteria)
- Preclinical AD - Biomarker abnormality, no cognitive symptoms
- MCI due to AD (Mild Neurocognitive Disorder) - Subtle cognitive decline, intact daily functioning
- Mild AD (Major Neurocognitive Disorder, mild) - Memory prominent, some functional impairment
- Moderate AD - More global deficits, increased dependency
- Severe AD - Profound cognitive decline, total dependency
Neuropathological Staging (Braak & Braak)
- Stages I-II: Neurofibrillary tangles confined to entorhinal cortex/transentorhinal region
- Stages III-IV: Involvement of hippocampus and limbic system
- Stages V-VI: Widespread neocortical involvement
Hallmark pathology: Amyloid plaques + neurofibrillary tangles in hippocampal and entorhinal regions on postmortem examination
(Bradley and Daroff's Neurology in Clinical Practice)
4. Proton Pump Inhibitors (PPIs)
Mechanism
PPIs cause irreversible blockade of the H+/K+-ATPase pump (proton pump) in the active parietal cells of the stomach. This produces long-lasting reduction of both stimulated and nocturnal acid secretion.
This is the classic example of a "hit and run" drug (see Section 5 below).
Classification / Examples
| Drug | Dose |
|---|---|
| Omeprazole | 20-40 mg OD |
| Lansoprazole | 15-30 mg OD |
| Pantoprazole | 40 mg OD |
| Rabeprazole | 20 mg OD |
| Esomeprazole | 20-40 mg OD |
| Dexlansoprazole | 30-60 mg OD |
All are benzimidazole derivatives, prodrugs activated by acid in the parietal cell canaliculus.
Clinical Uses
- Peptic ulcer disease
- Gastroesophageal reflux disease (GERD)
- Erosive gastritis
- Zollinger-Ellison syndrome
- H. pylori eradication (as part of triple/quadruple therapy)
- Stress ulcer prophylaxis
Pharmacokinetics
- Half-lives are much shorter than the duration of acid suppression (due to irreversible binding)
- Low toxicity overall
- May reduce absorption of drugs that require acidic pH (e.g., ketoconazole, atazanavir) and increase absorption of others
(Katzung's Basic and Clinical Pharmacology, 16th Edition)
5. "Hit and Run" Drugs
These are drugs that act irreversibly on their target - they bind covalently and their pharmacological effect outlasts their plasma half-life. The drug "hits" the target and then "runs" (is eliminated), but the effect persists until new target molecules are synthesized.
Key Concept
From Katzung's Pharmacology: Once an irreversible antagonist occupies the receptor, it need not remain in unbound form to inhibit agonist responses. The duration of action is relatively independent of the drug's own rate of elimination and is more dependent on the rate of turnover of receptor molecules.
Classic Examples
| Drug | Target | Effect Duration |
|---|---|---|
| Aspirin | COX-1/COX-2 (irreversible acetylation) | 7-10 days (life of platelet) |
| PPIs (omeprazole, etc.) | H+/K+-ATPase (irreversible blockade) | 24-48 hrs (until new pump synthesized) |
| Phenoxybenzamine | Alpha-adrenoceptors (covalent bond) | Days (used in pheochromocytoma) |
| Organophosphates (e.g., echothiophate) | Acetylcholinesterase (irreversible) | Weeks |
| Clopidogrel | P2Y12 ADP receptor on platelets | 7-10 days (life of platelet) |
| Cyclophosphamide | DNA alkylation | Cell-cycle dependent |
| Irreversible MAO inhibitors (phenelzine, tranylcypromine) | MAO enzyme | 2 weeks (enzyme regeneration) |
Clinical Significance of "Hit and Run" Drugs
- Overdose is difficult to reverse - cannot simply remove the drug; must wait for new receptor/enzyme synthesis
- Physiological antagonism may be needed (e.g., phenylephrine for phenoxybenzamine overdose)
- Withdrawal effects may occur after stopping irreversible MAOIs
- Pre-op planning - aspirin and clopidogrel must be stopped 5-7 days before surgery due to irreversible platelet inhibition
(Katzung's Basic and Clinical Pharmacology, 16th Edition, Chapter 2)
Summary Table: Hit and Run Drugs at a Glance
| Drug | Binds | Duration |
|---|---|---|
| Aspirin | COX enzymes | Platelet lifespan (~10 days) |
| PPIs | H+/K+-ATPase | ~24-48 hrs |
| Phenoxybenzamine | Alpha receptors | Days |
| Clopidogrel | P2Y12 receptor | Platelet lifespan |
| Organophosphates | Acetylcholinesterase | Weeks |
| Irreversible MAOIs | MAO-A/MAO-B | ~2 weeks |
This is a shared conversation. Sign in to Orris to start your own chat.